NCT03544567 - A Study of Oraxol in Subjects With Cutaneous Angiosarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 21, 2018

Primary Completion Date

May 12, 2023

Study Completion Date

May 12, 2023

Conditions

Angiosarcoma of Skin

Interventions

DRUG

Oraxol

oral paclitaxel will be supplied in capsules and oral HM30181A-US in tablets

Trial Locations (10)

Memorial Sloan Kettering Cancer Center, New York

Texas Oncology, Dallas

MD Anderson Cancer Center, Houston

University of Washington/Fred Hutchinson Cancer Center, Seattle

Prince of Wales Hospital, Shatin, Hong Kong

National Taiwan University Hospital, Taipei

Taipei Veterans General Hosptial, Taipei

University College London Hospitals NHS Foundation Trust, London

The Royal Marsden NHS Foundation Trust, London

The Christie NHS Foundation Trust, Manchester, Manchester